Core Viewpoint - The revenue of Tongyuan Kang Pharmaceutical-B (02410.HK) is primarily dependent on the exclusive licensing agreement with Lijun Pharmaceutical for the development and commercialization of the multi-target small molecule tyrosine kinase inhibitor TY-2136b in Greater China, with no milestone payments triggered as of June 30, 2025 [1] Financial Performance - The company's revenue for the six months ending June 30, 2024, and June 30, 2025, is reported as RMB 0 [1] - Research and development costs for the six months ending June 30, 2025, amounted to RMB 88.758 million, a decrease of 35.6% compared to RMB 137.758 million for the same period in 2024, primarily due to reduced trial and testing expenses [1] - The loss for the six months ending June 30, 2025, decreased to RMB 114 million from RMB 220 million for the same period in 2024 [1]